To examine the synergistic efficacy of CLK2 and PARP inhibition for increasing chemosensitivity in vivo, we utilized PDX models, which recapitulate patient tumor heterogeneity and histopathology and have been used to predict the clinical response to chemotherapy. This evidence concerns the gene CLK2 and neoplasm.